Lit­tle Ar­sa­nis steers its on­ly clin­i­cal-stage ther­a­py to the scrap heap af­ter a PhII im­plo­sion

One of the biotechs that bare­ly man­aged to com­plete its IPO late last year end­ed up of­fer­ing fresh proof about just how dan­ger­ous it can be to back a drug de­vel­op­er.

Ar­sa­nis $ASNS, a Vi­en­na-based com­pa­ny co-found­ed by an­ti­body ex­pert Till­man Gern­gross, re­port­ed to­day that it is scrap­ping its on­ly clin­i­cal de­vel­op­ment pro­gram af­ter the Phase II pro­gram for its S. au­reus pneu­mo­nia ther­a­py failed to sur­vive an in­ter­im analy­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.